Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range
- Sales of
$10.6 billion driven by strong underlying base business performance - Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical Devices
- Continues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data
- Third-quarter GAAP diluted EPS of
$0.94 and adjusted diluted EPS of$1.21 , which excludes specified items. Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales2.Abbott now projects full-year diluted EPS on a GAAP basis of$3.34 to$3.40 and projects adjusted diluted EPS of$4.64 to$4.70 , which represents an increase at the midpoint of the guidance range.- In October,
Abbott 's board of directors authorized a new share repurchase program of up to$7 billion of the company's common shares. - In August,
Abbott announced a unique global partnership with Medtronic to collaborate on connectingAbbott 's world-leading continuous glucose monitoring (CGM) system with Medtronic's insulin delivery devices. - In September,
Abbott announced theU.S. launch of Lingo™, the company's first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness. - In September,
Abbott announced a partnership with theBig Ten Conference ® to conduct a nationwide blood donation competition to help increase theU.S. blood supply. - In September,
Abbott completed enrollment ahead of schedule in its VOLT-AF IDE trial, which is designed to evaluate the Volt™ Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).
"Our results this quarter demonstrate the strength of our diversified business model," said
THIRD-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.
Note: In order to compute results excluding the impact of exchange rates, current year
|
Third Quarter 2024 Results (3Q24) |
|||||||||
|
Sales 3Q24 ($ in millions) |
|
Nutrition |
Diagnostics |
Established |
Medical Devices |
||||
|
|
4,202 |
950 |
1,032 |
— |
2,216 |
||||
|
International |
6,433 |
1,116 |
1,380 |
1,406 |
2,531 |
||||
|
Total reported |
10,635 |
2,066 |
2,412 |
1,406 |
4,747 |
||||
|
% Change vs. 3Q23 |
|||||||||
|
|
10.1 |
10.4 |
1.8 |
n/a |
14.2 |
||||
|
International |
1.7 |
(7.9) |
(3.8) |
2.7 |
9.6 |
||||
|
Total reported |
4.9 |
(0.3) |
(1.5) |
2.7 |
11.7 |
||||
|
Impact of foreign exchange |
(2.5) |
(3.1) |
(2.9) |
(4.3) |
(1.6) |
||||
|
Impact of business exit* |
(0.2) |
(0.6) |
— |
— |
— |
||||
|
Organic |
7.6 |
3.4 |
1.4 |
7.0 |
13.3 |
||||
|
Impact of COVID-19 testing sales (3) |
(0.6) |
— |
(1.9) |
— |
— |
||||
|
Organic (excluding COVID-19 tests) |
8.2 |
3.4 |
3.3 |
7.0 |
13.3 |
||||
|
|
11.0 |
11.9 |
2.4 |
n/a |
14.2 |
||||
|
International |
6.5 |
(2.6) |
3.8 |
7.0 |
12.5 |
||||
|
First Nine Months 2024 Results (9M24) |
|||||||||
|
Sales 9M24 ($ in millions) |
|
Nutrition |
Diagnostics |
Established |
Medical Devices |
||||
|
|
11,982 |
2,761 |
2,775 |
— |
6,435 |
||||
|
International |
18,994 |
3,523 |
4,046 |
3,926 |
7,499 |
||||
|
Total reported |
30,976 |
6,284 |
6,821 |
3,926 |
13,934 |
||||
|
% Change vs. 9M23 |
|||||||||
|
|
4.2 |
8.1 |
(16.2) |
n/a |
14.3 |
||||
|
International |
3.4 |
(1.1) |
(2.4) |
2.1 |
10.1 |
||||
|
Total reported |
3.7 |
2.7 |
(8.5) |
2.1 |
12.0 |
||||
|
Impact of foreign exchange |
(3.0) |
(3.1) |
(2.9) |
(7.3) |
(1.6) |
||||
|
Impact of business exit and acquisition* |
0.1 |
(0.4) |
— |
— |
0.4 |
||||
|
Organic |
6.6 |
6.2 |
(5.6) |
9.4 |
13.2 |
||||
|
Impact of COVID-19 testing sales (3) |
(2.8) |
— |
(10.4) |
— |
— |
||||
|
Organic (excluding COVID-19 tests) |
9.4 |
6.2 |
4.8 |
9.4 |
13.2 |
||||
|
|
10.0 |
9.0 |
3.0 |
n/a |
13.3 |
||||
|
International |
9.0 |
4.2 |
5.9 |
9.4 |
13.1 |
||||
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
|
*Quarter to date |
|
Nutrition |
|||||
|
Third Quarter 2024 Results (3Q24) |
|||||
|
Sales 3Q24 ($ in millions) |
Total |
Pediatric |
Adult |
||
|
|
950 |
568 |
382 |
||
|
International |
1,116 |
387 |
729 |
||
|
Total reported |
2,066 |
955 |
1,111 |
||
|
% Change vs. 3Q23 |
|||||
|
|
10.4 |
12.2 |
7.9 |
||
|
International |
(7.9) |
(21.6) |
1.5 |
||
|
Total reported |
(0.3) |
(4.5) |
3.6 |
||
|
Impact of foreign exchange |
(3.1) |
(1.8) |
(4.4) |
||
|
Impact of business exit* |
(0.6) |
— |
(1.1) |
||
|
Organic |
3.4 |
(2.7) |
9.1 |
||
|
|
11.9 |
12.2 |
11.5 |
||
|
International |
(2.6) |
(18.0) |
8.0 |
||
Worldwide Nutrition sales decreased 0.3 percent on a reported basis and increased 3.4 percent on an organic basis in the third quarter, led by growth in Adult Nutrition.
In Adult Nutrition, global sales increased 3.6 percent on a reported basis and 9.1 percent on an organic basis, which was led by growth of Ensure®,
|
First Nine Months 2024 Results (9M24) |
|||||
|
Sales 9M24 ($ in millions) |
Total |
Pediatric |
Adult |
||
|
|
2,761 |
1,646 |
1,115 |
||
|
International |
3,523 |
1,377 |
2,146 |
||
|
Total reported |
6,284 |
3,023 |
3,261 |
||
|
% Change vs. 9M23 |
|||||
|
|
8.1 |
11.8 |
3.2 |
||
|
International |
(1.1) |
(6.8) |
2.8 |
||
|
Total reported |
2.7 |
2.5 |
3.0 |
||
|
Impact of foreign exchange |
(3.1) |
(1.6) |
(4.4) |
||
|
Impact of business exit* |
(0.4) |
— |
(0.7) |
||
|
Organic |
6.2 |
4.1 |
8.1 |
||
|
|
9.0 |
11.8 |
5.0 |
||
|
International |
4.2 |
(3.6) |
9.7 |
||
|
*Reflects the impact of discontinuing the ZonePerfect® product line. This action was initiated in |
|
Diagnostics |
|||||||||
|
Third Quarter 2024 Results (3Q24) |
|||||||||
|
Sales 3Q24 ($ in millions) |
Total |
|
Molecular |
Point of Care |
Rapid |
||||
|
|
1,032 |
332 |
37 |
103 |
560 |
||||
|
International |
1,380 |
982 |
91 |
43 |
264 |
||||
|
Total reported |
2,412 |
1,314 |
128 |
146 |
824 |
||||
|
% Change vs. 3Q23 |
|||||||||
|
|
1.8 |
4.5 |
(2.8) |
6.0 |
(0.2) |
||||
|
International |
(3.8) |
(1.5) |
(3.9) |
0.7 |
(12.2) |
||||
|
Total reported |
(1.5) |
— |
(3.6) |
4.4 |
(4.4) |
||||
|
Impact of foreign exchange |
(2.9) |
(4.3) |
(1.5) |
(0.2) |
(1.4) |
||||
|
Organic |
1.4 |
4.3 |
(2.1) |
4.6 |
(3.0) |
||||
|
Impact of COVID-19 testing sales (3) |
(1.9) |
(0.2) |
(3.9) |
— |
(3.4) |
||||
|
Organic (excluding COVID-19 tests) |
3.3 |
4.5 |
1.8 |
4.6 |
0.4 |
||||
|
|
2.4 |
4.8 |
4.5 |
6.0 |
(1.0) |
||||
|
International |
3.8 |
4.4 |
0.8 |
1.3 |
2.8 |
||||
As expected, Diagnostics sales growth in the third quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales3. Worldwide COVID-19 testing sales were
Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2 percent on a reported basis and increased 3.3 percent on an organic basis.
Excluding COVID-19 testing-related sales, global
|
First Nine Months 2024 Results (9M24) |
|||||||||
|
Sales 9M24 ($ in millions) |
Total |
|
Molecular |
Point of Care |
Rapid |
||||
|
|
2,775 |
969 |
112 |
308 |
1,386 |
||||
|
International |
4,046 |
2,879 |
272 |
133 |
762 |
||||
|
Total reported |
6,821 |
3,848 |
384 |
441 |
2,148 |
||||
|
% Change vs. 9M23 |
|||||||||
|
|
(16.2) |
5.6 |
(12.3) |
6.6 |
(29.8) |
||||
|
International |
(2.4) |
0.3 |
(7.2) |
4.8 |
(10.6) |
||||
|
Total reported |
(8.5) |
1.5 |
(8.7) |
6.0 |
(24.0) |
||||
|
Impact of foreign exchange |
(2.9) |
(4.8) |
(0.8) |
(0.1) |
(1.1) |
||||
|
Organic |
(5.6) |
6.3 |
(7.9) |
6.1 |
(22.9) |
||||
|
Impact of COVID-19 testing sales (3) |
(10.4) |
(0.2) |
(6.3) |
— |
(25.0) |
||||
|
Organic (excluding COVID-19 tests) |
4.8 |
6.5 |
(1.6) |
6.1 |
2.1 |
||||
|
|
3.0 |
5.9 |
(3.3) |
6.6 |
(0.1) |
||||
|
International |
5.9 |
6.7 |
(0.9) |
5.1 |
5.7 |
||||
|
|
|||||
|
Third Quarter 2024 Results (3Q24) |
|||||
|
Sales 3Q24 ($ in millions) |
Total |
Key Emerging |
Other |
||
|
|
— |
— |
— |
||
|
International |
1,406 |
994 |
412 |
||
|
Total reported |
1,406 |
994 |
412 |
||
|
% Change vs. 3Q23 |
|||||
|
|
n/a |
n/a |
n/a |
||
|
International |
2.7 |
0.7 |
8.1 |
||
|
Total reported |
2.7 |
0.7 |
8.1 |
||
|
Impact of foreign exchange |
(4.3) |
(4.7) |
(3.1) |
||
|
Organic |
7.0 |
5.4 |
11.2 |
||
|
|
n/a |
n/a |
n/a |
||
|
International |
7.0 |
5.4 |
11.2 |
||
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for
|
First Nine Months 2024 Results (9M24) |
|||||
|
Sales 9M24 ($ in millions) |
Total |
Key Emerging |
Other |
||
|
|
— |
— |
— |
||
|
International |
3,926 |
2,910 |
1,016 |
||
|
Total reported |
3,926 |
2,910 |
1,016 |
||
|
% Change vs. 9M23 |
|||||
|
|
n/a |
n/a |
n/a |
||
|
International |
2.1 |
0.7 |
6.4 |
||
|
Total reported |
2.1 |
0.7 |
6.4 |
||
|
Impact of foreign exchange |
(7.3) |
(9.0) |
(2.2) |
||
|
Organic |
9.4 |
9.7 |
8.6 |
||
|
|
n/a |
n/a |
n/a |
||
|
International |
9.4 |
9.7 |
8.6 |
||
|
Medical Devices |
|||||||||||||||
|
Third Quarter 2024 Results (3Q24) |
|||||||||||||||
|
Sales 3Q24 ($ in millions) |
Total |
Rhythm |
Electro- physiology |
Heart |
Vascular |
Structural |
Neuro- |
Diabetes |
|||||||
|
|
2,216 |
288 |
285 |
252 |
258 |
270 |
190 |
673 |
|||||||
|
International |
2,531 |
309 |
325 |
70 |
441 |
288 |
46 |
1,052 |
|||||||
|
Total reported |
4,747 |
597 |
610 |
322 |
699 |
558 |
236 |
1,725 |
|||||||
|
% Change vs. 3Q23 |
|||||||||||||||
|
|
14.2 |
6.0 |
15.8 |
16.7 |
2.8 |
21.1 |
0.8 |
23.6 |
|||||||
|
International |
9.6 |
5.7 |
9.2 |
5.2 |
4.5 |
9.2 |
17.8 |
13.3 |
|||||||
|
Total reported |
11.7 |
5.9 |
12.2 |
14.0 |
3.9 |
14.6 |
3.8 |
17.1 |
|||||||
|
Impact of foreign exchange |
(1.6) |
(1.1) |
(2.1) |
(0.4) |
(1.0) |
(1.9) |
(1.4) |
(2.0) |
|||||||
|
Organic |
13.3 |
7.0 |
14.3 |
14.4 |
4.9 |
16.5 |
5.2 |
19.1 |
|||||||
|
|
14.2 |
6.0 |
15.8 |
16.7 |
2.8 |
21.1 |
0.8 |
23.6 |
|||||||
|
International |
12.5 |
7.9 |
13.0 |
6.6 |
6.2 |
12.6 |
25.7 |
16.5 |
|||||||
Worldwide Medical Devices sales increased 11.7 percent on a reported basis and 13.3 percent on an organic basis in the third quarter, including double-digit organic growth in both the
Sales growth was led by double-digit growth in Diabetes Care, Structural Heart, Heart Failure, and Electrophysiology. Several products contributed to the strong performance, including FreeStyle Libre®,
In Electrophysiology, sales grew 12.2 percent on a reported basis and 14.3 percent on an organic basis, which included double-digit growth in catheters and cardiac mapping-related products.
In Diabetes Care, sales of continuous glucose monitors exceeded
|
First Nine Months 2024 Results (9M24) |
|||||||||||||||
|
Sales 9M24 ($ in millions) |
Total |
Rhythm |
Electro- physiology |
Heart |
Vascular |
Structural |
Neuro- |
Diabetes |
|||||||
|
|
6,435 |
851 |
841 |
733 |
787 |
761 |
563 |
1,899 |
|||||||
|
International |
7,499 |
915 |
983 |
215 |
1,325 |
876 |
142 |
3,043 |
|||||||
|
Total reported |
13,934 |
1,766 |
1,824 |
948 |
2,112 |
1,637 |
705 |
4,942 |
|||||||
|
% Change vs. 9M23 |
|||||||||||||||
|
|
14.3 |
6.4 |
15.3 |
11.0 |
7.4 |
16.7 |
6.5 |
24.3 |
|||||||
|
International |
10.1 |
4.8 |
12.6 |
8.2 |
4.2 |
10.3 |
16.5 |
13.5 |
|||||||
|
Total reported |
12.0 |
5.6 |
13.8 |
10.4 |
5.4 |
13.2 |
8.4 |
17.4 |
|||||||
|
Impact of foreign exchange |
(1.6) |
(1.2) |
(2.6) |
(0.1) |
(1.3) |
(1.9) |
(1.5) |
(1.9) |
|||||||
|
Impact of acquisition* |
0.4 |
— |
— |
— |
2.8 |
— |
— |
— |
|||||||
|
Organic |
13.2 |
6.8 |
16.4 |
10.5 |
3.9 |
15.1 |
9.9 |
19.3 |
|||||||
|
|
13.3 |
6.4 |
15.3 |
11.0 |
0.1 |
16.7 |
6.5 |
24.3 |
|||||||
|
International |
13.1 |
7.1 |
17.4 |
8.9 |
6.0 |
13.7 |
24.6 |
16.5 |
|||||||
|
* |
On
About
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
|
1 |
In the third quarter of 2024, total worldwide sales were |
|
2 |
|
|
3 |
Diagnostic sales and COVID-19 testing-related sales in 2024 and 2023 are summarized below: |
|
Sales 3Q24 |
COVID Tests Sales 3Q24 |
|||||||||||
|
($ in millions) |
|
Int'l |
Total |
|
Int'l |
Total |
||||||
|
|
1,032 |
1,380 |
2,412 |
206 |
59 |
265 |
||||||
|
|
332 |
982 |
1,314 |
1 |
2 |
3 |
||||||
|
Molecular |
37 |
91 |
128 |
2 |
1 |
3 |
||||||
|
|
560 |
264 |
824 |
203 |
56 |
259 |
||||||
|
Sales 3Q23 |
COVID Tests Sales 3Q23 |
|||||||||||
|
($ in millions) |
|
Int'l |
Total |
|
Int'l |
Total |
||||||
|
|
1,013 |
1,436 |
2,449 |
207 |
98 |
305 |
||||||
|
|
317 |
997 |
1,314 |
2 |
3 |
5 |
||||||
|
Molecular |
38 |
95 |
133 |
5 |
3 |
8 |
||||||
|
|
561 |
301 |
862 |
200 |
92 |
292 |
||||||
|
Sales 9M24 |
COVID Tests Sales 9M24 |
|||||||||||
|
($ in millions) |
|
Int'l |
Total |
|
Int'l |
Total |
||||||
|
|
2,775 |
4,046 |
6,821 |
428 |
143 |
571 |
||||||
|
|
969 |
2,879 |
3,848 |
3 |
5 |
8 |
||||||
|
Molecular |
112 |
272 |
384 |
7 |
3 |
10 |
||||||
|
|
1,386 |
762 |
2,148 |
418 |
135 |
553 |
||||||
|
Sales 9M23 |
COVID Tests Sales 9M23 |
|||||||||||
|
($ in millions) |
|
Int'l |
Total |
|
Int'l |
Total |
||||||
|
|
3,309 |
4,145 |
7,454 |
1,031 |
267 |
1,298 |
||||||
|
|
917 |
2,872 |
3,789 |
6 |
10 |
16 |
||||||
|
Molecular |
128 |
293 |
421 |
19 |
17 |
36 |
||||||
|
|
1,975 |
853 |
2,828 |
1,006 |
240 |
1,246 |
||||||
|
Condensed Consolidated Statement of Earnings Third Quarter Ended (in millions, except per share data) (unaudited) |
||||||
|
3Q24 |
3Q23 |
% Change |
||||
|
|
|
|
4.9 |
|||
|
Cost of products sold, excluding amortization expense |
4,698 |
4,605 |
2.0 |
|||
|
Amortization of intangible assets |
470 |
496 |
(5.1) |
|||
|
Research and development |
713 |
672 |
6.1 |
|||
|
Selling, general, and administrative |
2,895 |
2,723 |
6.3 |
|||
|
Total Operating Cost and Expenses |
8,776 |
8,496 |
3.3 |
|||
|
Operating Earnings |
1,859 |
1,647 |
12.8 |
|||
|
Interest expense, net |
51 |
69 |
(26.0) |
|||
|
Net foreign exchange (gain) loss |
(11) |
(10) |
n/m |
|||
|
Other (income) expense, net |
(121) |
(83) |
n/m |
|||
|
Earnings before taxes |
1,940 |
1,671 |
16.1 |
|||
|
Taxes on earnings |
294 |
235 |
25.6 |
|||
|
Net Earnings |
|
|
14.6 |
|||
|
Net Earnings excluding Specified Items, as described below |
|
|
5.9 |
1) |
||
|
Diluted Earnings per Common Share |
|
|
14.6 |
|||
|
Diluted Earnings per Common Share, excluding Specified Items, as described below |
|
|
6.1 |
1) |
||
|
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options |
1,748 |
1,748 |
||||
|
NOTES: |
|
|
See table tilted "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. |
|
|
n/m = Percent change is not meaningful. |
|
|
See footnotes on the following section. |
|
|
1) |
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
|
2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
|
|
Condensed Consolidated Statement of Earnings Nine Months Ended (in millions, except per share data) (unaudited) |
||||||
|
9M24 |
9M23 |
% Change |
||||
|
|
|
|
3.7 |
|||
|
Cost of products sold, excluding amortization expense |
13,764 |
13,419 |
2.6 |
|||
|
Amortization of intangible assets |
1,413 |
1,485 |
(4.9) |
|||
|
Research and development |
2,095 |
2,041 |
2.6 |
|||
|
Selling, general, and administrative |
8,790 |
8,225 |
6.9 |
|||
|
Total Operating Cost and Expenses |
26,062 |
25,170 |
3.5 |
|||
|
Operating Earnings |
4,914 |
4,698 |
4.6 |
|||
|
Interest expense, net |
170 |
182 |
(6.4) |
|||
|
Net foreign exchange (gain) loss |
(17) |
17 |
n/m |
|||
|
Other (income) expense, net |
(222) |
(370) |
n/m |
|||
|
Earnings before taxes |
4,983 |
4,869 |
2.3 |
|||
|
Taxes on earnings |
810 |
740 |
9.6 |
1) |
||
|
Net Earnings |
|
|
1.0 |
|||
|
Net Earnings excluding Specified Items, as described below |
|
|
2.5 |
2) |
||
|
Diluted Earnings per Common Share |
|
|
1.3 |
|||
|
Diluted Earnings per Common Share, excluding Specified Items, as described below |
|
|
2.5 |
2) |
||
|
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options |
1,749 |
1,750 |
||||
|
NOTES: |
|
|
See table tilted "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. |
|
|
n/m = Percent change is not meaningful. |
|
|
See footnotes on the following section. |
|
|
1) |
2024 Taxes on Earnings includes the recognition of approximately |
|
2023 Taxes on Earnings includes the recognition of approximately |
|
|
2) |
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
|
2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
|
|
Non-GAAP Reconciliation of Financial Information Third Quarter Ended (in millions, except per share data) (unaudited) |
|||||
|
3Q24 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 470 |
$ (470) |
$ — |
||
|
Gross Margin |
5,467 |
516 |
5,983 |
||
|
R&D |
713 |
(19) |
694 |
||
|
SG&A |
2,895 |
(5) |
2,890 |
||
|
Other (income) expense, net |
(121) |
(12) |
(133) |
||
|
Earnings before taxes |
1,940 |
552 |
2,492 |
||
|
Taxes on Earnings |
294 |
79 |
373 |
||
|
Net Earnings |
1,646 |
473 |
2,119 |
||
|
Diluted Earnings per Share |
$ 0.94 |
$ 0.27 |
$ 1.21 |
||
Specified items reflect intangible amortization expense of
|
3Q23 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 496 |
$ (496) |
$ — |
||
|
Gross Margin |
5,042 |
542 |
5,584 |
||
|
R&D |
672 |
(46) |
626 |
||
|
SG&A |
2,723 |
(43) |
2,680 |
||
|
Other (income) expense, net |
(83) |
(23) |
(106) |
||
|
Earnings before taxes |
1,671 |
654 |
2,325 |
||
|
Taxes on Earnings |
235 |
90 |
325 |
||
|
Net Earnings |
1,436 |
564 |
2,000 |
||
|
Diluted Earnings per Share |
$ 0.82 |
$ 0.32 |
$ 1.14 |
||
Specified items reflect intangible amortization expense of
|
Non-GAAP Reconciliation of Financial Information Nine Months Ended (in millions, except per share data) (unaudited) |
|||||
|
9M24 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 1,413 |
$ (1,413) |
$ — |
||
|
Gross Margin |
15,799 |
1,540 |
17,339 |
||
|
R&D |
2,095 |
(81) |
2,014 |
||
|
SG&A |
8,790 |
(96) |
8,694 |
||
|
Other (income) expense, net |
(222) |
(183) |
(405) |
||
|
Earnings before taxes |
4,983 |
1,900 |
6,883 |
||
|
Taxes on Earnings |
810 |
222 |
1,032 |
||
|
Net Earnings |
4,173 |
1,678 |
5,851 |
||
|
Diluted Earnings per Share |
$ 2.38 |
$ 0.95 |
$ 3.33 |
||
Specified items reflect intangible amortization expense of
|
9M23 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 1,485 |
$ (1,485) |
$ — |
||
|
Gross Margin |
14,964 |
1,591 |
16,555 |
||
|
R&D |
2,041 |
(144) |
1,897 |
||
|
SG&A |
8,225 |
(67) |
8,158 |
||
|
Other (income) expense, net |
(370) |
34 |
(336) |
||
|
Earnings before taxes |
4,869 |
1,768 |
6,637 |
||
|
Taxes on Earnings |
740 |
189 |
929 |
||
|
Net Earnings |
4,129 |
1,579 |
5,708 |
||
|
Diluted Earnings per Share |
$ 2.35 |
$ 0.90 |
$ 3.25 |
||
Specified items reflect intangible amortization expense of
A reconciliation of the third-quarter tax rates for 2024 and 2023 is shown below:
|
3Q24 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 1,940 |
$ 294 |
15.2 % |
|||
|
Specified items |
552 |
79 |
||||
|
Excluding specified items |
$ 2,492 |
$ 373 |
15.0 % |
|||
|
3Q23 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 1,671 |
$ 235 |
14.0 % |
|||
|
Specified items |
654 |
90 |
||||
|
Excluding specified items |
$ 2,325 |
$ 325 |
14.0 % |
|||
A reconciliation of the year-to-date tax rates for 2024 and 2023 is shown below:
|
9M24 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 4,983 |
$ 810 |
16.3 % |
1) |
||
|
Specified items |
1,900 |
222 |
||||
|
Excluding specified items |
$ 6,883 |
$ 1,032 |
15.0 % |
|||
|
9M23 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 4,869 |
$ 740 |
15.2 % |
2) |
||
|
Specified items |
1,768 |
189 |
||||
|
Excluding specified items |
$ 6,637 |
$ 929 |
14.0 % |
|||
|
1) |
2024 Taxes on Earnings includes the recognition of approximately |
|
2) |
2023 Taxes on Earnings includes the recognition of approximately |
|
Non-GAAP Revenue Reconciliation Third Quarter and Nine Months Ended September 30, 2024 and 2023 ($ in millions) (unaudited) |
|||||||||||||
|
3Q24 |
3Q23 |
% Change vs. 3Q23 |
|||||||||||
|
Non-GAAP |
|||||||||||||
|
|
Impact from |
Adjusted |
|
Impact from |
Adjusted |
Reported |
Adjusted |
Organic |
|||||
|
|
10,635 |
(5) |
10,630 |
10,143 |
(17) |
10,126 |
4.9 |
5.1 |
7.6 |
||||
|
|
4,202 |
(5) |
4,197 |
3,817 |
(17) |
3,800 |
10.1 |
10.4 |
10.4 |
||||
|
Intl |
6,433 |
— |
6,433 |
6,326 |
— |
6,326 |
1.7 |
1.7 |
5.8 |
||||
|
Total Nutrition |
2,066 |
(5) |
2,061 |
2,073 |
(17) |
2,056 |
(0.3) |
0.3 |
3.4 |
||||
|
|
950 |
(5) |
945 |
860 |
(17) |
843 |
10.4 |
11.9 |
11.9 |
||||
|
Intl |
1,116 |
— |
1,116 |
1,213 |
— |
1,213 |
(7.9) |
(7.9) |
(2.6) |
||||
|
Adult Nutrition |
1,111 |
(5) |
1,106 |
1,072 |
(17) |
1,055 |
3.6 |
4.7 |
9.1 |
||||
|
|
382 |
(5) |
377 |
354 |
(17) |
337 |
7.9 |
11.5 |
11.5 |
||||
|
Intl |
729 |
— |
729 |
718 |
— |
718 |
1.5 |
1.5 |
8.0 |
||||
|
Total Medical Devices |
4,747 |
— |
4,747 |
4,249 |
— |
4,249 |
11.7 |
11.7 |
13.3 |
||||
|
|
2,216 |
— |
2,216 |
1,940 |
— |
1,940 |
14.2 |
14.2 |
14.2 |
||||
|
Intl |
2,531 |
— |
2,531 |
2,309 |
— |
2,309 |
9.6 |
9.6 |
12.5 |
||||
|
Vascular |
699 |
— |
699 |
672 |
— |
672 |
3.9 |
3.9 |
4.9 |
||||
|
|
258 |
— |
258 |
251 |
— |
251 |
2.8 |
2.8 |
2.8 |
||||
|
Intl |
441 |
— |
441 |
421 |
— |
421 |
4.5 |
4.5 |
6.2 |
||||
|
9M24 |
9M23 |
% Change vs. 9M23 |
|||||||||||
|
Non-GAAP |
|||||||||||||
|
|
Impact of |
Impact from |
Adjusted |
|
Impact from |
Adjusted |
Reported |
Adjusted |
Organic |
||||
|
|
30,976 |
(57) |
(13) |
30,906 |
29,868 |
(32) |
29,836 |
3.7 |
3.6 |
6.6 |
|||
|
|
11,982 |
(53) |
(13) |
11,916 |
11,503 |
(32) |
11,471 |
4.2 |
3.9 |
3.9 |
|||
|
Intl |
18,994 |
(4) |
— |
18,990 |
18,365 |
— |
18,365 |
3.4 |
3.4 |
8.3 |
|||
|
Total Nutrition |
6,284 |
— |
(13) |
6,271 |
6,116 |
(32) |
6,084 |
2.7 |
3.1 |
6.2 |
|||
|
|
2,761 |
— |
(13) |
2,748 |
2,553 |
(32) |
2,521 |
8.1 |
9.0 |
9.0 |
|||
|
Intl |
3,523 |
— |
— |
3,523 |
3,563 |
— |
3,563 |
(1.1) |
(1.1) |
4.2 |
|||
|
Adult Nutrition |
3,261 |
— |
(13) |
3,248 |
3,167 |
(32) |
3,135 |
3.0 |
3.7 |
8.1 |
|||
|
|
1,115 |
— |
(13) |
1,102 |
1,081 |
(32) |
1,049 |
3.2 |
5.0 |
5.0 |
|||
|
Intl |
2,146 |
— |
— |
2,146 |
2,086 |
— |
2,086 |
2.8 |
2.8 |
9.7 |
|||
|
Total Medical Devices |
13,934 |
(57) |
— |
13,877 |
12,444 |
— |
12,444 |
12.0 |
11.6 |
13.2 |
|||
|
|
6,435 |
(53) |
— |
6,382 |
5,631 |
— |
5,631 |
14.3 |
13.3 |
13.3 |
|||
|
Intl |
7,499 |
(4) |
— |
7,495 |
6,813 |
— |
6,813 |
10.1 |
10.0 |
13.1 |
|||
|
Vascular |
2,112 |
(57) |
— |
2,055 |
2,004 |
— |
2,004 |
5.4 |
2.6 |
3.9 |
|||
|
|
787 |
(53) |
— |
734 |
733 |
— |
733 |
7.4 |
0.1 |
0.1 |
|||
|
Intl |
1,325 |
(4) |
— |
1,321 |
1,271 |
— |
1,271 |
4.2 |
3.9 |
6.0 |
|||
|
(a) |
|
|
(b) |
Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in |
|
Details of Specified Items Third Quarter Ended (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ — |
$ 2 |
$ 470 |
$ 44 |
$ 516 |
||||
|
R&D |
— |
— |
— |
(19) |
(19) |
||||
|
SG&A |
(7) |
2 |
— |
— |
(5) |
||||
|
Other (income) expense, net |
(5) |
— |
— |
(7) |
(12) |
||||
|
Earnings before taxes |
$ 12 |
$ — |
$ 470 |
$ 70 |
552 |
||||
|
Taxes on Earnings (d) |
79 |
||||||||
|
Net Earnings |
$ 473 |
||||||||
|
Diluted Earnings per Share |
$ 0.27 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the |
|
d) |
Reflects the net tax benefit associated with the specified items. |
|
Details of Specified Items Third Quarter Ended (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ 3 |
$ 19 |
$ 496 |
$ 24 |
$ 542 |
||||
|
R&D |
(1) |
(13) |
— |
(32) |
(46) |
||||
|
SG&A |
(22) |
(22) |
— |
1 |
(43) |
||||
|
Other (income) expense, net |
5 |
— |
— |
(28) |
(23) |
||||
|
Earnings before taxes |
$ 21 |
$ 54 |
$ 496 |
$ 83 |
654 |
||||
|
Taxes on Earnings (d) |
90 |
||||||||
|
Net Earnings |
$ 564 |
||||||||
|
Diluted Earnings per Share |
$ 0.32 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as legal and other costs related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the |
|
d) |
Reflects the net tax benefit associated with the specified items. |
|
Details of Specified Items Nine Months Ended (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ 2 |
$ 76 |
$ 1,413 |
$ 49 |
$ 1,540 |
||||
|
R&D |
(4) |
(1) |
— |
(76) |
(81) |
||||
|
SG&A |
(32) |
(17) |
— |
(47) |
(96) |
||||
|
Other (income) expense, net |
(140) |
— |
— |
(43) |
(183) |
||||
|
Earnings before taxes |
$ 178 |
$ 94 |
$ 1,413 |
$ 215 |
1,900 |
||||
|
Taxes on Earnings (d) |
222 |
||||||||
|
Net Earnings |
$ 1,678 |
||||||||
|
Diluted Earnings per Share |
$ 0.95 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments. |
|
d) |
Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. |
|
Details of Specified Items Nine Months Ended (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ 15 |
$ 51 |
$ 1,485 |
$ 40 |
$ 1,591 |
||||
|
R&D |
(13) |
(5) |
— |
(126) |
(144) |
||||
|
SG&A |
(43) |
(28) |
— |
4 |
(67) |
||||
|
Other (income) expense, net |
46 |
— |
— |
(12) |
34 |
||||
|
Earnings before taxes |
$ 25 |
$ 84 |
$ 1,485 |
$ 174 |
1,768 |
||||
|
Taxes on Earnings (d) |
189 |
||||||||
|
Net Earnings |
$ 1,579 |
||||||||
|
Diluted Earnings per Share |
$ 0.90 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." |
|
|
a) |
Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments. |
|
d) |
Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. |
View original content:https://www.prnewswire.com/news-releases/abbott-reports-third-quarter-2024-results-and-raises-midpoint-of-full-year-eps-guidance-range-302277755.html
SOURCE
Abbott Financial: Michael Comilla, 224-668-1872, or Tamika LeBean, 224-399-5082, or Ryan Aliff, 224-667-2299; Abbott Media: Karen Twigg May, 224-668-2681, or Kate Dyer, 224-668-9965
